Name: Bristol Myers Buying RayzeBio For $4.1 Billion; RYZB Soars
Uploaded: 2023-12-26T11:39:38-05:00
Duration: 5 min
Description: Bristol Myers Squibb (BMY) said Tuesday it would acquire cancer drug developer RayzeBio (RYZB) in a deal valued at $4.1 billion. RYZB stock soared 100% on the news while BMY stock traded slightly lower. X Bristol Myers will pay $62.50 per share for RayzeBio, a 104% premium to the company’s Friday closing price of $30.57. […]

Tag: RYZB

Bristol Myers Buying RayzeBio For $4.1 Billion; RYZB Soars

Bristol Myers Squibb (BMY) said Tuesday it would acquire cancer drug developer RayzeBio (RYZB) in a deal valued at $4.1 billion. RYZB stock soared 100% on the news while BMY stock traded slightly lower. X Bristol Myers will pay $62.50 per share for RayzeBio, a 104% premium to the company’s Friday closing price of $30.57. […]